Scholarlink

<p>Antimicrobial resistance (AMR) in <i>Escherichia coli (E.coli)</i> poses a significant global threat to public health due to increasing resistance against antibiotics. This study explored a novel combination therapy by investigating the synergistic potential of three distinct antibiotics to combat AMR in <i>E. coli</i> isolates. Multi drug resistant (MDR), extensive drug resistant (XDR), and pan drug resistant (PDR) <i>E. coli</i> isolates were confirmed using the automated system Vitek followed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Dual and triple combinations of meropenem, ceftazidime, and polymyxin B were evaluated using a checkerboard assay and were further corroborated using field emission scanning electron microscopy (FE-SEM). Checkerboard assays demonstrated significant bactericidal activity up to 24 h for all MDR, XDR, and PDR isolates treated with combinations of meropenem + polymyxin B; ceftazidime + polymyxin B and meropenem + ceftazidime + polymyxin B. Notably, few of the XDR and PDR isolates showed no bacterial growth for up to 96 h with meropenem + polymyxin B; ceftazidime + polymyxin B; and meropenem + ceftazidime + polymyxin B combinations. FE-SEM images supported these findings, revealing significant plasmolysis with meropenem + polymyxin B; ceftazidime + polymyxin B; and meropenem + ceftazidime + polymyxin B treatments compared to the control. Dual and triple combination regimens were found to be effective for treating MDR, XDR, and PDR isolates. The present study suggested a promising strategy in in vitro conditions, but its effectiveness still requires further in vivo validation considering pharmacokinetics/pharmacodynamics (PK-PD) modeling and dynamic dosing regimens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Meropenem, Ceftazidime, and Polymyxin B combination therapy: a novel approach to combat antimicrobial resistance in MDR, XDR and PDR Escherichia coli

  • 期刊论文

  • 发表日期：

    2026年2月17日

查看全文
  • Siddhi A. Darji,
  • Avani Raulji,
  • Axita Patel,
  • Himanshu Pandya,
  • Rupal Patel,
  • Chirag Patel,
  • Bhaskar Datta,
  • Devjani Banerjee

摘要

Antimicrobial resistance (AMR) in Escherichia coli (E.coli) poses a significant global threat to public health due to increasing resistance against antibiotics. This study explored a novel combination therapy by investigating the synergistic potential of three distinct antibiotics to combat AMR in E. coli isolates. Multi drug resistant (MDR), extensive drug resistant (XDR), and pan drug resistant (PDR) E. coli isolates were confirmed using the automated system Vitek followed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Dual and triple combinations of meropenem, ceftazidime, and polymyxin B were evaluated using a checkerboard assay and were further corroborated using field emission scanning electron microscopy (FE-SEM). Checkerboard assays demonstrated significant bactericidal activity up to 24 h for all MDR, XDR, and PDR isolates treated with combinations of meropenem + polymyxin B; ceftazidime + polymyxin B and meropenem + ceftazidime + polymyxin B. Notably, few of the XDR and PDR isolates showed no bacterial growth for up to 96 h with meropenem + polymyxin B; ceftazidime + polymyxin B; and meropenem + ceftazidime + polymyxin B combinations. FE-SEM images supported these findings, revealing significant plasmolysis with meropenem + polymyxin B; ceftazidime + polymyxin B; and meropenem + ceftazidime + polymyxin B treatments compared to the control. Dual and triple combination regimens were found to be effective for treating MDR, XDR, and PDR isolates. The present study suggested a promising strategy in in vitro conditions, but its effectiveness still requires further in vivo validation considering pharmacokinetics/pharmacodynamics (PK-PD) modeling and dynamic dosing regimens.